HUTCHMED Announces Board of Directors and Board Committee Membership
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or...
Cancer
Mendus AB: Mendus AB (publ) Interim Report January – March 2023
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the...
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology...
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no...
Orion Corporation: Managers’ transactions – Mikael Silvennoinen
ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MAY 2023 at 15.30 EEST Orion Corporation: Managers’ transactions – Mikael Silvennoinen Orion Corporation...
Orion Corporation: Managers’ transactions – Agendum Oy
ORION CORPORATION MANAGERS’ TRANSACTIONS 11 MAY 2023 at 15.30 EEST Orion Corporation: Managers’ transactions – Agendum Oy Orion Corporation...
Scotiabank donates $1.35M to the MUHC Foundation to create a Montreal without hepatitis C
The transformative gift supports Montréal sans HépC, an ambitious community-based program to prevent and cure hepatitis C cases in Montreal...
Oncocyte Reports First Quarter 2023 Financial Results
Nearing Manufacturing Start Up of First Kitted ProductIRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Cash on Hand of $15.5M Expected to Support Completion of the CAReS Trial and Operations into Second Half of 2024SOLANA...
RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 millionSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins...
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE...
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-WALTHAM, Mass.,...
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion...
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to...
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists...
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published...